IXICO CEO says milestone Medidata collaboration supports growth strategy

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden talked with Proactiv's Stephen Gunnion about the company’s new collaboration with Medidata and how it supports IXICO’s growth strategy in the clinical trials space. Goorden described the agreement as a significant milestone, highlighting Medidata’s position as “a multibillion dollar player in the clinical trial space” with a global footprint across thousands of trials. The partnership combines Medidata’s electronic data capture and clinical trial technologies with IXICO’s proprietary neuroimaging analytics to create a more seamless solution for biopharma clients. He explained that the collaboration strengthens IXICO’s ability to scale, giving the company access to larger and more complex clinical trials. Goorden noted that the deal aligns with IXICO’s long-term ambition to expand its presence in high-value studies while enhancing operational reach. The CEO also pointed to recent commercial momentum, including a £1.5 million contract extension for a global Phase 2 trial and the appointment of a new chief commercial officer, Tanya Voloshen. These developments reflect what he described as “a very busy quarter” for the company. Looking ahead, Goorden emphasised that the Medidata collaboration represents the beginning of a broader “tech bio strategy,” adding that it is expected to support recurring revenue streams and accelerate growth. For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content. #IXICO #Medidata #ClinicalTrials #Biotech #Neuroimaging #TechBio #Pharma #HealthcareInnovation #LifeSciences #CEOInterview